ReviewInflammopharmacology2025
Targeting the redox neuroinflammatory nexus: insights into Alzheimer's and Parkinson's diseases.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Epigenetic regulators polyphenols in neurodegenerative diseases: a promising intervention strategy.Annals of medicine · 2026Review
- An engineered ROS-responsive cascade nanoplatform delays Alzheimer's disease progression via Nrf2/GPX4-mediated microglial functional reprogramming.Materials today. Bio · 2026Article
- Decoding shared pathogenic networks of oxidative stress in neuropsychiatric disorders to prioritize multi-target therapeutics from natural products.Cell biology and toxicology · 2026Article
- Bibliometric analysis of nanomaterials in the diagnosis and treatment of neurological and psychiatric disorders (1997-2025): trends and future directions.Journal of nanobiotechnology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases, including Alzheimer's and Parkinson's, are characterized by the progressive deterioration of neuronal structure and function within the central and peripheral nervous systems. Among the multifactorial mechanisms implicated in their pathogenesis, oxidative stress and chronic neuroinflammation have emerged as pivotal contributors. An imbalance in redox homeostasis, marked by excessive generation of reactive oxygen species (ROS) and impaired antioxidant defenses, leads to sustained activation of inflammatory pathways and exacerbation of neuronal injury. This intricate interplay, known as the redox-neuroinflammatory nexus, constitutes a central axis in the onset and progression of neurodegeneration. This review underscores the critical role of redox imbalance in neurodegenerative processes and provides a comprehensive analysis of the oxidative stress and inflammation crosstalk in Alzheimer's and Parkinson's diseases, offering insights into potential therapeutic targets.
Indexed as
Identifiers
40601284What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.